Sign in
EPIX Stock Price, Chart, Stats & News
ESSA Pharma Inc.
Save
EPIX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 2.98% |
Operating margin | -21920.00% |
Pretax margin | -18611.02% |
Net margin | -18611.02% |
Effective tax rate | – |
ROA | -22.86% |
ROE | -21.70% |
D/E | – |
Interest coverage ratio | – |
EPIX valuation
P/E | – |
P/S | 70.12x |
P/B | 0.08x |
P/CF | -0.43x |
P/FCF | -0.46x |
P/OCF | -0.43x |
PEG | -0.03x |
EV multiple | -3.65x |
About
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer.
Similar securities
Based on sector and market capitalization
Report issue